

GENOME THERAPEUTICS CORP  
Form 8-K  
October 16, 2003

---

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to

Section 13 or 15(d) of

**THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of Earliest Event Reported): October 16, 2003

---

**GENOME THERAPEUTICS CORP.**

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other jurisdiction

of incorporation)

**0-10824**  
(Commission File Number)

**04-2297484**  
(I.R.S. Employer

Identification Number)

**100 Beaver Street**

**Waltham, Massachusetts 02453**

(Address, of principal executive offices, including zip code)

**(781) 398-2300**

(Registrant's Telephone number including area code)

---

---

**Page 1 of 4 pages.**

Item 5. OTHER EVENTS

On October 16, 2003, Genome Therapeutics Corp. ( Genome ), a Massachusetts corporation, issued a press release announcing it raised approximately \$3.5 million in gross proceeds through a private placement to accredited investors of approximately 1,400,000 shares of Genome Common Stock and warrants to purchase approximately 700,000 shares of Genome Common Stock. The warrants have an exercise price of \$3.48 per share. A copy of the press release is attached hereto as Exhibit 99.1.

The securities issued in the private placement have not been registered under the Securities Act of 1933, as amended, and until so registered the securities may not be offered or sold in the United States absent registration or availability of an applicable exemption from registration. Pursuant to a Registration Rights Agreement, Genome is required to prepare and file with the Securities and Exchange Commission within 20 business days after the closing date, a registration statement for the purpose of registering for resale all of the shares of Genome s Common Stock sold and issuable upon exercise of the warrants sold in the private placement.

The foregoing description of the private placement does not purport to be complete and is qualified in its entirety by reference to the form of Subscription Agreement, the form of Registration Rights Agreement, and the form of Warrant, in each case, incorporated by reference herein from the exhibits to the Company s Current Report on Form 8-K filed on October 1, 2003.

Item 7. Financial Statements and Exhibits.

(c) Exhibits

- 4.1 Form of Warrant issued by the Company to each investor.\*
- 10.1 Form of Subscription Agreement by and among the Company and each investor.\*
- 10.2 Form of Registration Rights Agreement.\*
- 99.1 Press Release dated October 16, 2003.

---

\* Incorporated by reference from the Company s Current Report on Form 8-K filed on October 1, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By                                  /s/ Stephen Cohen

Name: Stephen Cohen

Title: Senior Vice President and  
Chief

Financial Officer

Date: October 16, 2003

EXHIBIT INDEX

- 4.1 Form of Warrant issued by the Company to each investor.\*
- 10.1 Form of Subscription Agreement by and among the Company and each investor.\*
- 10.2 Form of Registration Rights Agreement.\*
- 99.1 Press Release dated October 16, 2003.

---

\* Incorporated by reference from the Company's Current Report on Form 8-K filed on October 1, 2003.